Literature DB >> 17158753

Significance, detection and markers of disseminated breast cancer cells.

Marc Lacroix1.   

Abstract

The development of distant metastases is the major cause of death from breast cancer. In order to predict and prevent tumour spreading, many attempts are being made to detect small numbers of tumour cells that have shed from the primary lesions and have moved to lymph nodes, blood or bone marrow. This article presents the advantages and the limitations of techniques used for disseminated tumour cells (DTC) detection. DTC markers are listed and the most currently used of them (KRT19, CEACAM5, TACSTD1, MUC1, EGFR, ERBB2, SCGB2A2, SCGB2A1, SCGB1D2, PIP, SBEM, TFF1, TFF3, ANKRD30A, SPDEF, ESR1, SERPINB5 and GABRP) are discussed, notably on the basis of recent data on breast tumour portraits (luminal epithelial-like, basal/myoepithelial-like and ERBB2). The significance of DTC for the prognosis and prediction of response to therapy is examined. DTC viability, the notion of cell dormancy and the concept of breast cancer stem cells are also discussed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17158753     DOI: 10.1677/ERC-06-0001

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  106 in total

1.  Selection of brain metastasis-initiating breast cancer cells determined by growth on hard agar.

Authors:  Lixia Guo; Dominic Fan; Fahao Zhang; Janet E Price; Ju-Seog Lee; Dario Marchetti; Isaiah J Fidler; Robert R Langley
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

2.  CXCL12, CXCR4 and IFNγ genes expression: implications for proinflammatory microenvironment of breast cancer.

Authors:  Karen Brajão de Oliveira; Roberta Losi Guembarovski; Alda Maria Fiorina Losi Guembarovski; Ana Cristina da Silva do Amaral Herrera; Walter Jorge Sobrinho; Carolina Batista Ariza; Maria Angelica Ehara Watanabe
Journal:  Clin Exp Med       Date:  2012-06-15       Impact factor: 3.984

3.  Keratin 19 expression correlates with poor prognosis in breast cancer.

Authors:  Nuzhat N Kabir; Lars Rönnstrand; Julhash U Kazi
Journal:  Mol Biol Rep       Date:  2014-08-26       Impact factor: 2.316

4.  Combined SFK/MEK inhibition prevents metastatic outgrowth of dormant tumor cells.

Authors:  Lara H El Touny; Anthony Vieira; Arnulfo Mendoza; Chand Khanna; Mark J Hoenerhoff; Jeffrey E Green
Journal:  J Clin Invest       Date:  2013-12-09       Impact factor: 14.808

5.  Is transplantation of cryopreserved ovarian tissue from patients with advanced-stage breast cancer safe? A pilot study.

Authors:  V Luyckx; J F Durant; A Camboni; S Gilliaux; C A Amorim; A Van Langendonckt; L M Irenge; J L Gala; J Donnez; M M Dolmans
Journal:  J Assist Reprod Genet       Date:  2013-08-29       Impact factor: 3.412

6.  Cyclooxygenase-2 expression in primary breast cancers predicts dissemination of cancer cells to the bone marrow.

Authors:  Anthony Lucci; Savitri Krishnamurthy; Balraj Singh; Isabelle Bedrosian; Funda Meric-Bernstam; James Reuben; Kristine Broglio; Kailash Mosalpuria; Ashutosh Lodhi; Laura Vincent; Massimo Cristofanilli
Journal:  Breast Cancer Res Treat       Date:  2008-07-29       Impact factor: 4.872

7.  Chromatin context dominates estrogen regulation of pS2 gene expression.

Authors:  Akua K Oduro; Michael K Fritsch; Fern E Murdoch
Journal:  Exp Cell Res       Date:  2008-07-15       Impact factor: 3.905

8.  AZGP1 and SPDEF mRNA expression differentiates breast carcinoma from ovarian serous carcinoma.

Authors:  Helene Tuft Stavnes; Dag André Nymoen; Anita Langerød; Arild Holth; Anne-Lise Børresen Dale; Ben Davidson
Journal:  Virchows Arch       Date:  2012-12-15       Impact factor: 4.064

Review 9.  Models, mechanisms and clinical evidence for cancer dormancy.

Authors:  Julio A Aguirre-Ghiso
Journal:  Nat Rev Cancer       Date:  2007-11       Impact factor: 60.716

10.  Expression analysis of human pterygium shows a predominance of conjunctival and limbal markers and genes associated with cell migration.

Authors:  C J Jaworski; M Aryankalayil-John; M M Campos; R N Fariss; J Rowsey; N Agarwalla; T W Reid; N Dushku; C A Cox; D Carper; G Wistow
Journal:  Mol Vis       Date:  2009-11-20       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.